Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States

Journal of General Internal Medicine

Volumn 22, Issue 2, 2007, Pages 197-204

  Woloshin, Steven ^a,b,c   Schwartz, Lisa M ^a,b,c   Kerin, Kevin ^a,b   Welch, H Gilbert ^a,b,c  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Antilipemic agents; C reactive protein; Coronary disease; Guideline adherence; Risk assessment

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CERVISTATIN; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FEMALE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; UNITED STATES; ALGORITHM; BLOOD; HEALTH CARE PLANNING; HYPERCHOLESTEROLEMIA; METABOLISM; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINE;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTILIPEMIC AGENTS; C-REACTIVE PROTEIN; FEMALE; GUIDELINE ADHERENCE; HEALTH PLANNING GUIDELINES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PATIENT SELECTION; UNITED STATES;

EID: 34250348365     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-006-0033-z     Document Type: Article

References (39)

1. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of c-reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557-65.
2. Grady D. Study says a protein may be better than cholesterol in predicting heart disease. NY Times. 2002(November 17);A26.
3. Brown D. New test for risk of heart disease; study shifts focus from cholesterol. Washington Post. 2002(November 14);A1.
4. USNWR cover. Special report: the heart test that could save your life. US News and World Report. 2002(November 25);54.
5. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation. 2003;107:499-511.
6. Ridker P, Cannon C, Morrow D, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction. N Engl J Med. 2005;352:20-8.
7. Nissen S, Tuzcu E, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
8. Cook N, Burine J, Ridker P. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21-9.
9. Folsom A, Chambless L, Ballantyne C, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers. Arch Intern Med. 2006;166:1368-73.
10. Lloyd-Jones D, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35-42.
11. Kolata G. Protein's link to heart disease is a mystery. NY Times. 2005(January 11);F5.
12. Department of Health and Human Services Centers for Medicare and Medicaid Services. Program memorandum intermediaries/carriers. 2002 Clinical Laboratory Fee Schedule and Laboratory Costs Subject to Reasonable Charge Payment Methodology. Implementation date January 1, 2002, Download AB-01-162. http://www.cms.hhs.gov/Transmittals/CMSPM/itemdetail.asp?filterType=dual, %20keyword&filterValue=162&filterByDID=0&sortByDID=4&sortOrder= ascending&itemID=CMS025696&intNumPerPage=10 [accessed December 2, 2006].
13. CRPhealth.com. Your source of information on C-reactive protein. Online presentations. Presentations on CRP for patients. An introduction to high sensitivity c-reactive protein (hs-CRP) for patients: can we better predict heart attack and stroke? http://www.crphealth.com/conf/hcp/5,22/doctor.paul.m. ridker.an.introduction.to.high-sensitivity.c-reactive.protein.html [accessed July 26, 2006]
14. National Health and Nutrition Examination Survey. Public-use data files. http://www.cdc.gov/nchs/about/major/nhanes/datalink.htm [accessed December 2, 2006].
15. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) full report. http://www.nhlbi.nih.gov/guidelines/ cholesterol/atp3_rpt.htm [accessed July 27 2006].
16. Centers for Disease Control and Prevention. NHANES 2000-1 analytic guidelines (June 2004 version). http://www.cdc.gov/nchs/nhanes.htm. [accessed July 26, 2006].
17. The National Health and Nutrition Examination Survey. 1999-2000 addendum to the NHANES III analytic guidelines. http://www.cdc.gov/nchs/data/nhanes/ guidelines1.pdf [accessed July 26, 2006].
18. The National Health and Nutrition Examination Survey. Analytic and reporting guidelines. Last update: December, 2005. http://www.cdc.gov/nchs/data/ nhanes/nhanes_03_04/nhanes_analytic_guidelines_dec_2005.pdf [accessed July 27, 2006].
19. Wilson P, D'Agostino R, Levy D, Belanger A, Silbershatz H, Kannel W. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;12:1837-47.
20. Law M, Wald N, Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-30.
21. Ridker PM. C-reactive protein a simple test to help predict risk of heart attack and stroke. Circulation. 2003;108:e81-5.
22. Ridker PM. Clinical application of c-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-9.
23. Ridker PM, Wilson PWF, Grundy SM. Should c-reactive protein be added to metabolic syndrome an the assessment of global cardiovascular risk? Circulation. 2004;109:2818-25.
24. Smith SC, Anderson JL, Cannon RO, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice report from the clinical practice discussion group. Circulation. 2004;110:e550-3.
25. Brigham and Women's Hospital. Cardiovascular Center. Understanding C-reactive protein-a simple test to help predict risk of heart attack and stroke. http://www.brighamandwomens.org/publications/publications.aspx [accessed July 27, 2006].
26. The 2006 Statistical Abstract: The National Data Book. US Census Bureau. Estimates and projections by age, sex, race/ethnicity. Table 12 - Resident Population Projections by Sex and Age: 2005 to 2050. http://www.census.gov/ compendia/statab/population/ [accessed December 1, 2006].
27. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001;161:53-8.
28. Hsia J, Rodabough R, Rosal M, et al. Compliance with National Cholesterol Education Program dietary and lifestyle guidelines among older women with self-reported hypercholesterolemia. The women's health initiative. Am J Med. 2002;113:384-92.
29. Henkin Y, Shai I, Zuk R, et al. Dietary treatment of hypercholesterolemia: do dietitians do it better? A randomized, controlled trial. Am J Med. 2000;109:549-55.
30. Hammett C, Prapavessis H, Baldi J, et al. Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk. Am Heart J. 2006;151:367e8-16.
31. Estruch R, Martinez-Gonzalez M, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors. Ann Intern Med. 2006;145:1-11.
32. Esposito K, Pontillo A, Di Paolo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women. JAMA. 2003;289:1799-804.
33. Mora S, Ridker P. Justification for the use of statins in primary prevention: an intervention trial evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97(suppl):33A-41A.
34. Danesh J, Wheeler J, Hirschfield G, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
35. Davey Smith G, Timpson N, Lawlor D. C-reactive protein and cardiovascular risk: still an unknown quantity? Ann Intern Med. 2006;145:70-2.
36. Lloyd-Jones D, Tian L. Predicting cardiovascular risk: so what do we do now? Arch Intern Med. 2006;166:1342-4.
37. Ko D, Mamdani M, Alter D. Lipid-lowering therapy with statins in high risk elderly patients: the treatment risk paradox. JAMA. 2004;291:1864-70.
38. Majumdar S, Gurwitz J, Soumerai S. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 1999;14:711-7.
39. Woloshin S, Schwartz L. Distribution of high sensitivity C-reactive protein (CRP) values in the United States (letter). N Engl J Med. 2005;352:1611-3.